Supernus signs up Stefan Schwabe as CMO
This article was originally published in Scrip
CNS company Supernus Pharmaceuticals has appointed Dr Stefan Schwabe executive vice-president of R&D and chief medical officer. Dr Schwabe has over 24 years' experience, having worked in CNS at Ciba-Geigy, Novo Nordisk, Johnson & Johnson, Novartis and Sanofi in various capacities. Most recently, Dr Schwabe served as COO at DemeRx, a privately-held biotech company specialising in addiction.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.